In patients receiving a stent (BMS or DES) dur- ing PCI for ACS, P2Y12 inhibitor therapy should be given for at least 12 months. Options include (Level of Evidence: B) b. In patients receiving DES for a non-ACS indica- tion, clopidogrel 75 mg daily should be given for at least 12 months if the patient is not at high risk of bleeding.208,212,571 (Level of Evidence: B) c. In patients receiving BMS for a non-ACS indica- tion, clopidogrel should be given for a minimum of 1 month and ideally up to 12 months (unless the patient is at increased risk of bleeding; then it should be given for a minimum of 2 weeks).572 (Level of Evidence: B) 3. Patients should be counseled on the importance of compliance with DAPT and that therapy should not be discontinued before discussion with their cardi- ologist.208 (Level of Evidence: C) Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e613 Table 14. Postprocedural Recommendations for Patients Undergoing PCI Recommendations COR LOE References Aspirin After PCI, use of aspirin should be continued indefinitely. I A 560 563 After PCI, it is reasonable to use aspirin 81 mg/d in preference to higher maintenance doses. IIa B 302,573 576 In patients receiving a stent (BMS or DES) during PCI for ACS, P2Y12 inhibitor therapy should be given for at least 12 mo. Options include clopidogrel 75 mg/d, prasugrel 10 mg/d, and ticagrelor 90 mg twice daily. I B 567,568,570 In patients receiving DES for a non-ACS indication, clopidogrel 75 mg/d should be given for at least 12 mo if patients are not at high risk of bleeding. 